Physician profile
Neritan Mani
NPI 1376511105
$8,923.76
in general payments reported to CMS, 2019-2025
23 companies · $1,827 in 2025
The $1,827 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $722 · 2021: $1,156 · 2022: $1,626 · 2023: $1,305 · 2024: $1,535 · 2025: $1,827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,667.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,042.42 | 2019-2024 | Watchman Flx, Watchman Access System |
| Janssen Pharmaceuticals, INC | $1,040.19 | 2019-2024 | Xarelto |
| Abbott Laboratories | $952.70 | 2024-2025 | Jot Dx |
| Astrazeneca Pharmaceuticals LP | $765.99 | 2020-2024 | Farxiga, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $651.38 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $644.64 | 2021-2025 | Lifevest |
| Medtronic, INC. | $495.03 | 2023-2025 | Micra, Linq II |
| Pfizer INC. | $386.11 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $332.41 | 2022-2023 | Ultomiris |
| Amgen INC. | $270.00 | 2022-2025 | Repatha |
| Bridgebio Pharma, INC. | $145.62 | 2025 | Attruby |
| Medtronic Vascular, INC. | $141.83 | 2019-2020 | |
| Biogen, INC. | $140.49 | 2021 | |
| Biotronik INC. | $133.14 | 2024 | Acticor 7 Vr-T Dx |
| Portola Pharmaceuticals, LLC | $126.79 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $125.00 | 2025 | |
| Scpharmaceuticals INC. | $122.14 | 2025 | |
| Abbvie INC. | $113.33 | 2023-2025 | |
| Inspire Medical Systems, INC. | $111.51 | 2024 | Inspire |
| Novartis Pharmaceuticals Corporation | $108.32 | 2020 | |
| Merck Sharp & Dohme LLC | $35.15 | 2024 | Dificid |
| Alnylam Pharmaceuticals INC. | $27.38 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neritan Mani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.